NASDAQ: PRTG - Portage Biotech Inc.

Yield per half year: +50.29%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Portage Biotech Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Portage Biotech Inc.

Portage Biotech Inc., together with its subsidiaries, research and develops pharmaceutical and biotechnology products.

more details
The company's product pipeline includes IMM60, an iNKT cell activator that is in phase I clinical trial; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; TT-4, an adenosine receptor type 2B (A2B) inhibitor to treat solid tumors; TT-53, an A2A/A2B inhibitor to treat solid tumors; TT-10, an adenosine receptor type 2A (A2A) inhibitor to treat A2A expressing solid tumors; TT-3, an A2B inhibitor to treat colorectal and gastrointestinal cancers; and INT230-6 for the treatment of tumors. It also provides Nanolipogel co-formulation platform for delivery of DNA aptamers and certain aptamer-small molecule-based combination products; and STING agonist platform, a proprietary immune priming and boosting technology, offers various ways to target immune stimulation towards the cancer, as well as to co-deliver various signals in a single product. The company is based in Tortola, British Virgin Islands.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2021-02-25
ISIN VGG7185A1286
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.portagebiotech.com
Цена ао 0.53
Change price per day: -5.9% (5.59)
Change price per week: -11.74% (5.96)
Change price per month: +24.94% (4.21)
Change price per 3 month: -24.1% (6.93)
Change price per half year: +50.29% (3.5)
Change price per year: +189.01% (1.82)
Change price per 3 year: -58.71% (12.74)
Change price per 5 year: +525 900% (0.001)
Change price per 10 year: 0% (5.26)
Change price per year to date: +26.75% (4.15)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV 59.02 1
P/E 0 0
EV/EBITDA -10.52 0
Total: 2.13

Efficiency

Title Value Grade
ROA, % -140.94 0
ROE, % -188.19 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.0026 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % -68.4 0
Yield Ebitda, % 208.46 10
Yield EPS, % 459.58 10
Total: 8
More

Institutions Volume Share, %
Armistice Capital, LLC 1876105 10.54
Bison Wealth, LLC 213398 1.2
Peak6 Investments Llc 51221 0.29
Blackrock Inc. 35240 0.2
Renaissance Technologies, LLC 21100 0.12
Citadel Advisors Llc 14139 0.08
Beacon Investment Advisory Services, Inc. 11395 0.06
IEQ CAPITAL, LLC 11250 0.06
Dimensional Fund Advisors LP 10565 0.06
Pathstone Holdings, LLC 10100 0.06



Head Job title Payment Year of birth
Dr. Ian B. Walters M.B.A., M.D. CEO & Chairman of Board 967.65k 1968 (57 years)
Mr. Allan J. Lee Shaw CPA Chief Financial Officer 524.08k 1964 (61 year)
Dr. Robert A. Kramer Ph.D. Chief Scientific Officer 310.16k
Mr. Brian Wiley Chief Business Officer 220.69k 1968 (57 years)
Mr. Justin Fairchild Vice President of Development 283.83k
Mr. Joseph Ciavarella Chief Accounting Officer N/A

Address: British Virgin Islands, Tortola VG, Clarence Thomas Building - open in Google maps, open in Yandex maps
Website: https://www.portagebiotech.com